华森制药：公司获得药品注册证书

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for its product Crizotinib capsules from the National Medical Products Administration [1] Group 1 - The announcement was made on the evening of October 20 [1] - The approval signifies a regulatory milestone for Huason Pharmaceutical in bringing Crizotinib to market [1]